HBIO vs. ZFOX, LTRX, AXTI, ARBE, CSPI, RELL, REKR, UEIC, SATL, and GWH
Should you be buying Harvard Bioscience stock or one of its competitors? The main competitors of Harvard Bioscience include ZeroFox (ZFOX), Lantronix (LTRX), AXT (AXTI), Arbe Robotics (ARBE), CSP (CSPI), Richardson Electronics (RELL), Rekor Systems (REKR), Universal Electronics (UEIC), Satellogic (SATL), and ESS Tech (GWH). These companies are all part of the "computer and technology" sector.
ZeroFox (NASDAQ:ZFOX) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking.
Harvard Bioscience has lower revenue, but higher earnings than ZeroFox. Harvard Bioscience is trading at a lower price-to-earnings ratio than ZeroFox, indicating that it is currently the more affordable of the two stocks.
Harvard Bioscience has a net margin of -8.18% compared to Harvard Bioscience's net margin of -152.73%. ZeroFox's return on equity of 0.26% beat Harvard Bioscience's return on equity.
ZeroFox has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.
In the previous week, Harvard Bioscience had 5 more articles in the media than ZeroFox. MarketBeat recorded 7 mentions for Harvard Bioscience and 2 mentions for ZeroFox. ZeroFox's average media sentiment score of 0.53 beat Harvard Bioscience's score of 0.00 indicating that Harvard Bioscience is being referred to more favorably in the news media.
ZeroFox currently has a consensus price target of $3.50, suggesting a potential upside of 207.02%. Given Harvard Bioscience's higher possible upside, equities research analysts plainly believe ZeroFox is more favorable than Harvard Bioscience.
Harvard Bioscience received 364 more outperform votes than ZeroFox when rated by MarketBeat users. Likewise, 72.02% of users gave Harvard Bioscience an outperform vote while only 44.44% of users gave ZeroFox an outperform vote.
37.3% of ZeroFox shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 12.8% of ZeroFox shares are owned by company insiders. Comparatively, 9.0% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Harvard Bioscience beats ZeroFox on 12 of the 16 factors compared between the two stocks.
Get Harvard Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Harvard Bioscience Competitors List
Related Companies and Tools
